The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril compositionShow others and affiliations
2019 (English)In: Amyloid: Journal of Protein Folding Disorders, ISSN 1350-6129, E-ISSN 1744-2818, Vol. 26, no Suppl. 1, p. 39-40Article in journal (Refereed) Published
Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD , 2019. Vol. 26, no Suppl. 1, p. 39-40
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
URN: urn:nbn:se:uu:diva-392843DOI: 10.1080/13506129.2019.1593133ISI: 000477775700022PubMedID: 31343354OAI: oai:DiVA.org:uu-392843DiVA, id: diva2:1350029
Conference
16th International Symposium on Amyloidosis (ISA), MAR 26-29, 2018, Kumamoto, JAPAN
2019-09-102019-09-102019-09-10Bibliographically approved